Webinar - Introducing the First ATP GMP Facility in Hong Kong
Dr Daniel Lee, Vice-President and Chief Innovation and Enterprise Officer, Office of Innovation and Enterprise of the Chinese University of Hong Kong, introduced the first Advanced Therapy Product (ATP) Good Manufacturing Practice (GMP) facility in Hong Kong to our members on 13 January 2022. Attracting 46 industry professionals, Dr Lee briefed our members about the operation model, scope and the services provided by the CUHK ATP GMP centre.
The facility aims to accelerate the development of ATPs from bench-to-bedside, while stimulating the testing and commercialisation process. Clinical trials in cell-based cancer therapies such as chimeric antigen receptor T-cell (CAR-T) and stem cell-based regenerative therapies will be the initial focus of the facility. As part of the launch, relevant scientists and operators will receive training to operate, audit and regulate both the facility, and the products manufactured.
Dr Daniel Lee is a clinical biochemist by training and obtained his PhD in Pathology at the University of Hong Kong. He has serviced the pharmaceutical industry for over 25 years including JNJ, Biogen, GSK and lately served as General Manager and Head of site for Roche Pharma R&D China in Shanghai from 2010. He has broad experience in the drug discovery and development business, familiar in both small molecule and biologic drug discovery and development covering therapeutic areas from CNS, infectious diseases, diabetes complications to oncology and inflammation. He is a member of the Innovation & Technology Fund Research Projects Assessment Panel, member and mentor of the Hong Kong Life Science Society (HKLSS).
He is currently Associate Vice-President and Chief Innovation and Enterprise Officer, Office of Innovation and Enterprise of the Chinese University of Hong Kong.